HORIZON 2020The EU Framework Programme for Research and Innovation

OVERVIEW OF RESEARCH ACTIVITIES IN INFECTIOUS DISEASES

OCTA - European Parliament 20th October 2015

Inmaculada Peñas Jiménez

'Fighting Infectious Diseases and Global Epidemics

DG Research & InnovationEuropean Commission 1

The role of the European Commission - Research and innovation

Develop and implement the European research and innovation policy agreed by the European Parliament and European Council.

Funds research through multi-annual framework programmes for research (since 1984). Implemented through annual work programmes and call for proposals and independent peer review of proposals.

The European Commission manages about 5% of total public spending in R&D in the European Union.

2

Key priorities for infectious diseases in the Health, Demographic Change and Wellbeing

Theme

• Emerging infectious diseases (EE)Influenza and other emerging diseases (incl vector-borne diseases)

• Anti-microbial resistance (AMR)

• Poverty-related diseases (PRD)HIV/AIDS, Tuberculosis, Malaria

• Neglected Infectious diseases (NID)

3

Some figures of the researchin major infectious diseases

funded by the FP7 (2007-2013)

4

Some FP7 projects…

• IDAMS € 6 million EU contribution - Start 01/09/2011 - 60 months• Is improving clinical and laboratory diagnosis and clinical management of dengue;

identifying markers to differentiate dengue from other febrile illness; likelihood to evolve to a more severe disease; risk of dengue spread and maps; and developing effective and affordable early warning systems and outbreak responses

• 18 participants from 14 countries including from Mexico,Malaysia and Ghana

• DENGUETOOLS € 6 million EU contribution - Start 01/09/2011 - 54 months• Developing early diagnostic tests, laboratory-based early warning systems, predictive

models and risk maps better surveillance as well as developing a community-based strategy to reduce dengue incidence in school aged children

• 15 participants from 11 countries including Brasil, Sri Lanka and Singapore

• DENFREE € 6 million EU contribution - Start 01/01/2012 - 60 months• Is identifying the key factors determining transmission, outcome of infection and

epidemics of dengue fever, as well as developing of novel diagnostic tools to detect asymptomatic infections, and estimating the risk of virus spreading to uninfected areas

• 15 participants from 11 countries including Cuba, Cambodia and French Polynesia

5

What is Horizon 2020?

− Responding to the economic crisis to invest in future jobs and growth

− Addressing people’s concerns about their livelihoods, safety and environment

− Strengthening the EU’s global position in research, innovation and technology

6http://ec.europa.eu/research/horizon2020

The EU’s 2014-20 programmefor research & innovation

A core part of Europe 2020, Innovation Union &European Research Area

•Excellent science

•Industrial leadership

•Societal challenges

• European Research Council• Future and Emerging Technologies• Marie Skłodowska-Curie actions• Research infrastructures

• Leadership in enabling and industrial technologies

• Access to risk finance

• Innovation in SMEs

SC1- Health, demographic changes

and wellbeing (€ 7.5 b)

The new EU programme for research and innovation € 79 billion (2014-2020)

HORIZON 2020 (2014-2020)

Collaborative projects

SME instrument

Financial instruments

Eureka Eurostars-2

AAL-2IMI-2

SC1 Health €7.5bn (of €31bn)

Industrial leadership €17bn

Excellent science €24bn

Health in H2020Future and Emerging

Technologies

LEIT Biotech

Marie Skłodowska Curie

Fast Track to Innovation

EDCTP-2

European Research Council

Research Infrastructures

8

Infectious Diseases R&I – Collaboration for innovative solutions – Implementation

1 – Collaborative research projects

Implemented by DG RTD

2 - Horizon prize

Implemented by DG RTD

3 – Global Initiatives

GLOPID- R ; GTBVP; World RePORT

4- Public–Private partnership

IMI2: From discovery to human testing to regulatory aspects, HTA and pharmacovigilence

5- Public–Public partnership

EDCTP2

Joint Programme on AMR

ERA-INFECT

6- Infectious Disease Finance Facility – INNOVFIN ID

jointly developed by EC and EIB 9

Infectious diseases in Horizon 2020 COLLABORATIVE RESEARCH

Priorities addressed in 2014-2015:

• Vaccine development for poverty related and neglected infectious diseases• 2014 – Tuberculosis € 25 million – 2 projects funded • 2015 – HIV/AIDS € 45 million – 2 projects funded

• 2014 – COMPARE - Development of web based system for rapid identification, containment and mitigation of emerging infectious diseases and foodborne outbreaks by generation and comparison of genomic information on samples and pathogens across sectors, time and locations, with contextual additional data.

• 2014 - I-MOVE+,a scientific public health platform to identify, pilot test, use and disseminate the best study designs to measure the effectivenes (direct effect)and the impact (indirect and overall effect) of influenza and pneumococcal vaccines

10

The challenges

• Ageing population

• Increased disease burden

• Unsustainable and unequal health & care systems

• Health & care sector under pressure to reform

11

Who's eligible for funding?• Horizon 2020 is open to participation from across the

world

• By default:

• Member States (including overseas departments and overseas territories)

• Associated Countries

• exhaustive list of countries in annex to workprogramme (but: no longer BRIC + Mexico in this list!)

• Participants from other countries are funded inexceptional cases:

• when provision is made in the call text

• bilateral agreement (e.g. USA, Health challenge – NIH)

• when the Commission deems it essential (case by case assessment)

12

Methods and data

Health care provision and integrated care

Active ageing and self-management of health

Treating and managing diseases

Preventing disease

Understanding health, well-being & disease

The Horizon 2020 Health Challenge:WP 2016-2017

'Personalised Medicine'

'coordination activities'

ERA-NETs , Joint Programming, Global Alliance for Chronic Diseases (GACD), Valorisation of FP7 results and other Coordination Actions

€ 930million13

Understanding the call topics: example

• 'PHC 2 – 2015'

• 'Specific challenge'

• 'Scope'

• 'Expected impact'

• 'Type of action'

14

Topics 2016-2017 - 1.1 Understanding health, well-being and disease:

• PM 01 – 2016 – Multi omics for personalised therapies [RTD]

• PM 02 – 2017- New concepts in patient stratification [RTD]

• PM 03 – 2016 – Diagnostic characterisation of rare diseases

• PM 04 – 2016 - Networking and optimising the use of population and patient cohorts at EU level [RTD]

15

Topics 2016-2017 - 1.2 Preventing diseases:

• PM-05–2016: The European Human Biomonitoring Initiative [RTD]

• PM-06–2016: Vaccine development for malaria and/or neglected infectious diseases [RTD]

• PM-07–2017: Promoting mental well-being in the young

16

Topics 2016-2017 - 1.3 Treating and managing diseases :

• PM 08 – 2017 - New therapies for rare diseases [RTD]

• PM 09 – 2016 - New therapies for chronic diseases [RTD]

• PM 10 – 2017 - Comparing the effectiveness of existing healthcare interventions in the adult population [RTD]

• PM 11 – 2016+2017 - Clinical research on regenerative medicine [RTD]

17

Topics 2016-2017 - 1.4 Active ageing and self-management of health:

• PM 12 – 2016 – PCP – eHealth innovation in empowering the patient [CNECT]

• PM 13 – 2016- PPI for deployment and scaling up of ICT solutions for active and healthy ageing [CNECT]

• PM 14 – 2016 – EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities [CNECT]

• PM 15 – 2017 - Personalised coaching for well-being and care of people as they age [CNECT]

18

Topics 2016-2017 - 1.5 Methods and data:

• PM 16 - 2017- In-silico trials for developing and assessing biomedical products [CNECT]

• PM 17 – 2017 - Personalised computer models and in-silico systems for well-being [CNECT]

• PM 18 – 2016 - Big Data supporting Public Health policies [CNECT]

• PM 19 – 2017 - PPI for uptake of standards for the exchange of digitalised healthcare records [CNECT]

• PM 20 - Development of new methods for improved economic evaluation and efficiency measures in the health sector [RTD]

1.6 Health care provision and integrated care:

• PM 21 - 2016- Implementation research for scaling-up of evidence based innovations and good practice in Europe and middle-income countries [RTD] 19

Topics 2016-2017 - Coordination activities:

• HCO 01 – 2016 - Valorisation of FP7 Health and H2020 SC1 research results [RTD]

• HCO 02 – 2016 - Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine [RTD]

• HCO 03 – 2017 - Implementing the Strategic Research Agenda on Personalised Medicine [RTD]

• HCO 04 – 2016 - Towards globalisation of the Joint Programming Initiative on Antimicrobial resistance [RTD]

• HCO 05 – 2016 - Coordinating personalised medicine research [RTD]

• HCO 06 – 2016 - Towards an ERA-NET for building sustainable and resilient health care models

• HCO 07– 2017 - Global Alliance for Chronic Diseases (GACD) [RTD]

• HCO 08 – 2017 - Actions to bridge the divide in European health research and innovation [RTD]

20

Topics 2016-2017 Co-ordination activities:

• HCO 09 – 2016 - EU m-health hub including evidence for the integration of mHealth in healthcare systems [CNECT]

• HCO 10 – 2016 - Support for Europe’s leading Health ICT SMEs [CNECT]

• HCO 11– 2016 - Coordinated Action to support the recognition of Silver Economy opportunities arising from demographic change [CNECT]

• HCO 12 – 2016 - Digital health literacy [CNECT]

• HCO 13 – 2016 – Healthcare workforce IT skills [CNECT]

• HCO 14 – 2016 - EU-US interoperability roadmap [CNECT]

• HCO 15- 2016 - EU eHealth Interoperability conformity assessment [CNECT]

• HCO 16- 2016 – Standardisation needs in the field of ICT for Active and Healthy Ageing [CNECT]

21

HORIZON PRIZE• The European Commission has launched the:

Horizon Prize for Better use of Antibiotics

• This challenge prize is offering a cash reward of

€1 million• To the person or team who can most effectively meet the following

challenge: Develop a rapid test that will allow healthcare providers to distinguish, at the point-of-care, between patients with upper respiratory tract infections that require antibiotics and those that can be treated safely without them

Upper Respiratory Tract Infections include pharyngitis, sinusitis, otitis and bronchitis

22

GLOPID-R A Global Research Collaboration for

Infectious Disease Preparedness

• A global multifunder initiative

• A network of research funders which aims to spark a collaborative global research response within 48 hours, after an outbreak

• Key funders from Australia, Brazil, Canada, China, South Africa, US, France, UK, Sweden, Spain, Germany

23

Facilitate exchange of information

Address scientific, legal, ethical and financial challenges

Implement a 'One Health' approach with close cooperation between human and animal health researchers

Establish a strategic agenda for research response

Connect infectious disease research networks

Create partnerships with low-income countries24

GloPID-R objectives

EDCTP2 (2014 – 2024)• Broader scope: support to clinical trials to bring

treatments, vaccines, diagnostics and delivery optimisation closer to the patients of HIV/AIDS, TB, malaria and neglected infectious diseases

• More EU co-funding€683 million from EU Horizon2020 + at least the same amount from participating countries

• Governance 28 full member countries: 14 African + 14 European countries

• Publication of work plan 2015http://www.edctp.org

25

26

Diseases: HIV/AIDS, TB, Malaria, NIDs, emerging infectious diseases of particular relevance for Africa, including Ebola

New tools and interventions: Diagnostics, drugs, vaccines and microbicides

Capacity Development: Fellowships, Networks, Ethics, Regulatory

General rules for participation: At least 2 legal entity in EU Member States or in countries associated to Horizon 2020 and one legal entity in Sub Saharan Africa

Get prepared!

Free of charge services to assist you:

•Call text, guide for applicants, FAQs: Participant portalhttp://ec.europa.eu/research/participants/portal/desktop/en/home.html

•Practical information & assistance: National Contact Points (NCPs), Enterprise Europe Network (EEN)

http://ec.europa.eu/research/participants/portal/desktop/en/support/national_contact_points.html

•Find partners, training, brokerage: Fit for Health 2.0http://www.fitforhealth.eu/

•Projects funded in FP7 Health: EU Health projects databasehttp://www.healthcompetence.eu/converis/publicweb/area/1353

•IP questions and advices: IPR helpdeskhttps://www.iprhelpdesk.eu/

• SME regulatory one stop shop: EMA SME office http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000059.jsp

• Become evaluator - select the best projects http://ec.europa.eu/research/participants/portal/desktop/en/experts/index.html

27

Thank you

www.ec.europa/research/horizon2020

http://ec.europa.eu/research/health/infectious-diseases/index_en.html

28